Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors Journal Articles

Overview
Research
Identity
Additional Document Info
View All

abstract

Learning Objectives After completing this course, the reader will be able to: Describe the mechanisms of action of sorafenib.Discuss the safety and toxicity data from phase I trials of sorafenib.Evaluate phase I and II trials of sorafenib with activity data.Discuss future areas for research in the development of this drug. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

authors

Strumberg, Dirk
Clark, Jeffrey W
Awada, Ahmad
Moore, Malcolm J
Richly, Heike
Hendlisz, Alain
Hirte, Holger
Eder, Joseph P
Lenz, Heinz-Josef
Schwartz, Brian

status

published

publication date

April 1, 2007

has subject area

1112 Oncology and Carcinogenesis (FoR)
Antineoplastic Agents (MeSH)
Benzenesulfonates (MeSH)
Clinical Trials, Phase I as Topic (MeSH)
Humans (MeSH)
Neoplasm Metastasis (MeSH)
Neoplasms (MeSH)
Niacinamide (MeSH)
Oncology & Carcinogenesis (Science Metrix)
Phenylurea Compounds (MeSH)
Protein Kinase Inhibitors (MeSH)
Pyridines (MeSH)
Sorafenib (MeSH)
raf Kinases (MeSH)

published in

Oncologist Journal